Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Vincent Andrews
Period: Reporting periods mapped to calendar 2024 Q4 – 2026 Q2 (7 quarters).
- Questions
- 86on tracked calls
- Challenge rate
- 6%5 of 86 questions
- Companies
- 12questioned at least once
- Reporting periods
- 7with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 86 of 86 questions from 12 companies
ALBAlbemarle Corporation13 questions · 7 reporting periods · 0 of 13 challenging
Calendar 2026 Q2
How do we think about the normalization of the bromine price versus the incremental cost, the $70 million to $90 million
Show response
Neal said it is too early to call whether the Middle East cost persists into 2027, but productivity work should lift Specialties margins regardless of bromine price normalization.
Calendar 2026 Q1
were you saying that these assets could potentially start up as early as 2028, or would the timeline on that be a bit longer?
Show response
Masters said brownfield growth is clearly after 2027 and fills the gap before bigger projects like Kings Mountain. None are finalized as projects yet and JV partner alignment is needed. This represents the next leg of growth.
As prices ramp higher than that, how much of that drops down to cash flow versus how much would go up to working capital?
Show response
Sheorey said sudden price spikes compress cash conversion in the near term from working capital build. Gradual increases should allow staying within the 60-70% long-term target range.
Calendar 2025 Q4
how do you assess sort of where customer inventory levels are and where customer behavior is as prices have gone up
Show response
Masters said lithium inventories are low across the supply chain. ESS shipments run about 6-12 months ahead of installations but the gap looks reasonably balanced. Post-Lunar New Year demand data will provide more clarity on 2026 trends.
what should the makings of AP, AR, inventories look like in 2026 just given what is happening from a price perspective
Show response
Sheorey noted production levels are up in 2026 with some going to restock inventories. Rising prices create a working capital cash flow headwind. Working capital typically runs at 25% of sales.
Calendar 2025 Q3
are you speaking of the energy storage segment or the company overall?
Show response
Masters confirmed the 30%+ adjusted EBITDA margin potential at $15/kg applies to the total company, not just Energy Storage.
there's also another language about liability management opportunity. What does that refer to?
Show response
Sheorey explained it refers to opportunities beyond gross deleveraging across the entire debt stack.
Calendar 2025 Q2
do your contracts skew a little bit more towards Atacama volume? Or are they evenly split geographically
Show response
Masters said contracts are split across locations but almost all long-term agreements are with Western players.
Could you just give us a sense of most recent reduction, what is that coming out of? And also, do you have an updated maintenance CapEx number
Show response
Masters declined to break out maintenance vs. growth CapEx but said cuts are coming from many small areas and expect to continue driving capital out.
Calendar 2025 Q1
do they give you complete credit for the $350 million in the net debt to EBITDA calculation, or do they haircut it
Show response
Sheorey confirmed rating agencies give full credit and are pleased with the company's broader financial flexibility actions.
Would you anticipate a similar amount of that this year to $50 million, or would it be less than that or a little bit more?
Show response
Sheorey said the prior year's miscellaneous financing outflows are a reasonable assumption for 2025.
Calendar 2024 Q4
You have a new line item that says inventory net realizable value adjustment. And this year, it's a negative $500 million
Show response
Sheorey explained the line item relates to the Q4 2023 lower-of-cost-or-market inventory charge.
I assume that's included when you talk about the 80% conversion as well as being free cash flow neutral this year
Show response
Sheorey confirmed the prepayment is included in 2025 metrics and noted Talison JV dividends resuming in 2026 would offset the non-recurrence.
DDDuPont8 questions · 6 reporting periods · 0 of 8 challenging
Calendar 2026 Q2
Is there any reversal of that? Or where you think overall conversion might be for the full year?
Show response
Franzen guided full-year FCF conversion closer to 100% than 90%, driven by working-capital productivity.
Calendar 2026 Q1
You called out some weakness in packaging. We've been hearing sort of mixed things about the packaging arena
Show response
Koch attributed packaging weakness to home and office printing decline against a tough Q1 2025 comp. Full year printing and packaging expected to normalize at up low single digits.
Calendar 2025 Q4
is that sort of the normal growth rate? And is that favorable or about the same versus 2025
Show response
Koch noted general surgical procedures ~4% growth, DuPont's market-weighted exposure at ~5% due to cardiovascular/vascular concentration. Similar trajectory to 2025 ex-destock.
can you just refresh us on sort of what the minimum level of cash is that you want to carry
Show response
Koch confirmed ~$1B cash target. Year-end was below that due to $500M ASR. Aramids proceeds coming Q1. No specific earmarking between M&A and buybacks, will deploy based on best shareholder value creation.
Calendar 2025 Q2
Just wanted to revisit ElectronicsCo and the margins and maybe some thoughts into the 3Q on the margins
Show response
Kemp explained apparent price decline is ICS mix effect (lower margin vs Semi), with underlying margins healthy from volume leverage and productivity.
Calendar 2025 Q1
whether you think there'll be any material developments between now and November spin either in the state attorney generals, or in the individual litigation?
Show response
Breen outlined NJ trial starting this month (multi-phase through summer) and PI bellwether cases in October, with nothing imminent before spin.
Calendar 2024 Q4
could you give us a sense of [indiscernible] had excellent conversion this year? What you think 2025 might look like?
Show response
Franzen guided >90% FCF conversion for 2025 excluding transaction costs, noting some working capital usage from growth investments.
is there a window between now and spin where you can get some assets out of the business without having to assing pro-rata [indiscernible] liabilities to them?
Show response
Koch confirmed a pre-spin divestiture window exists above $2.5B threshold, but noted full focus is on Electronics separation.
APDAir Products7 questions · 4 reporting periods · 1 of 7 challenging
Calendar 2026 Q2
no material financial impact for fiscal 2027. Is that for both the income statement and the cash flow statement?
Show response
Eduardo confirmed no NEOM P&L impact in 2027; Melissa added the JV contributions are largely complete (73% project-financed) so no large cash-flow impact, and the ~$500M CapEx cut reflects payment-timing on backlog execution.
Calendar 2026 Q1
on the tax rate, it came in a bit lower than we thought for the quarter. It was down about 1 point year-over-year and about 0.5 point sequentially
Show response
Melissa confirmed 18% ETR is the right forecast. Q2 benefited from U.S. investment tax credits and Dutch investment incentive that should flow through rest of year.
corporate and other the operating income hit was a lot less year-over-year and sequentially. You called out lower changes to sale of equipment
Show response
Melissa explained improvement driven by prior year sale of equipment cost increase on percentage of completion project. Run rate should be consistent for rest of year.
Calendar 2025 Q4
if you decide for whatever reason not to move forward with Daro, is it just that you sell the equipment and whatever else, and you recover $1 billion
Show response
Eduardo reiterated ~50% recovery is a rough estimate. Ammonia loop has best resale value as standard equipment. High-pressure hydrogen plants have limited market. Only spending on pre-committed equipment orders.
is it possible that the timing of final investment decision could move later into the year?
Show response
Eduardo maintained mid-year target. CBAM impact is indirect and Yara bears regulatory risk. 99% of decision is construction cost, not regulation. Two outcomes only: no-go or go-forward with a good project.
Calendar 2025 Q3
The slide speaks to lower changes of sale of equipment project estimates. What does that mean?
Show response
Melissa explained sale-of-equipment projects use percentage-of-completion accounting. Lower cost increases this year versus last year improved the corporate segment.
It looks to us like your CapEx forecast for fiscal '26 has gone from about $3.1 billion to $4 billion. So first of all, is that correct?
Show response
Melissa attributed the increase to a refined bottom-up review including new project wins across regions. Maintenance improvements could bring number down.
CFCF Industries7 questions · 5 reporting periods · 1 of 7 challenging
Calendar 2026 Q2
should we be anticipating maybe getting to more annual dividend increases versus, I think, the last 1 was maybe 2023?
Show response
Bohn tied dividend growth to rising free-cash-flow conversion and said CF retains some M&A scope after the Gulf Coast plant went to Yara, favoring low-cost North American assets.
Calendar 2026 Q1
On the buyback in the quarter, it was $15 million. Were you buying throughout the quarter? Were you locked up in some way?
Show response
Chris explained Q1 grid was kept in place but activity was lighter when conflict broke out due to uncertainty over duration. Emphasized shares trading below intrinsic value with $1.7 billion remaining on authorization. Intention to execute before authorization expires with no change in view of share value.
Calendar 2025 Q2
I think the press release talked about an expectation that China will not export further this year, at least after 3Q. So just curious what's driving that view
Show response
Bert said China initially offered 2M tons through Q3, then added 1M more, but has been underperforming actual shipments in June-July. China expected to build domestic inventory for spring season through Q4-Q1. Minimum export prices raised for both prilled and granular product.
Calendar 2025 Q1
What type of offtake agreements are you looking for? Do you feel the need to have them?
Show response
Tony cautioned against locking in large offtake volumes citing Mosaic ammonia contract as example of below-market returns over time. May consider small pieces but prefers Bert's ability to capture market upside.
I'd be curious what your plan is in terms of how you're going, to report Blue Point within your financials
Show response
Greg confirmed full consolidation of Blue Point JV into CF financials with 60% partner share removed through non-controlling interest. Blue Point will be reported within existing ammonia segment. Footnotes will provide clear breakout of legacy versus JV for comparability.
Calendar 2024 Q4
I assume that's the standard midpoint of -- there's plus or minus 15% on that? Or is there something different about this
Show response
Tony explained significant contingency baked in, almost $2B in lump-sum fixed modular construction to limit overrun risk. Chris noted peak contractor count of 1,500 vs 5,000 on prior projects.
what's going to drive the delta for you between the 40% and 75%
Show response
Tony explained both JERA and Mitsui partners have strong interest. Bringing partners helps spur new clean ammonia demand applications beyond CF's own needs.
CTVACorteva7 questions · 7 reporting periods · 0 of 7 challenging
Calendar 2026 Q2
Wondering if we could talk a little bit about in the seed business for the second half of the year
Show response
Judd O'Connor said the order book is ahead of the market and expects high single to low double digit Conkesta E3 penetration in 2027.
Calendar 2026 Q1
the S&D environment in crop chemicals is starting to improve with some developments out of China
Show response
Chuck explained higher energy costs adding inflation to AI production in India and China, with slight export slowdowns to Brazil, though 2026 impact is likely minimal.
Calendar 2025 Q4
it sounds like there is some existing licensing expense that was going through the income statement
Show response
David said eliminating Bayer royalties accelerates net neutral position to 2026. Post-2027 the agreement adds over $100M/year from freedom to operate and licensing offense. Judd confirmed HT4 access is not royalty-free, reciprocal royalties apply.
Calendar 2025 Q3
do you think there's any further pruning of the AI portfolio that you want to do?
Show response
Chuck said portfolio is strong with new actives like Rinskor, Arylex, Reklemel. Open to partnerships and JVs as industry needs more collaboration on resistance challenges.
Calendar 2025 Q2
one would just be the tough CP comp and the negative pricing in Brazil
Show response
David reminded H2 is only 12-13% of full year EBITDA. Judd said mid-single-digit acreage increases for Brazil summer and safrinha, plus Argentina rebound.
Calendar 2025 Q1
what's driving sort of the change in the sort of trajectory or cadence of the negative pricing?
Show response
Robert said pricing pressure will soften as they lap prior year. China generic pricing stabilized. Chuck added channel inventories now healthy, on-farm demand strong, industry feeling more encouraged.
Calendar 2024 Q4
what stands out to me is it looks like the production cost in crop chem or crop protection came in a lot lower
Show response
Robert confirmed CP cost program on track with $200M more takeout planned in 2025. Chuck explained deliberate decision to clear high-cost seed inventory from 2023 quality issues.
DOWDow Inc.7 questions · 7 reporting periods · 0 of 7 challenging
Calendar 2026 Q2
Do you have any just sort of site level update on that project's progression?
Show response
Carter said Alberta is ~60% of CapEx spent, on plan, incentives intact, and remains open to accretive partners that meet return thresholds.
Calendar 2026 Q1
if you think when we get to the other side of the conflict, there could be any changes in the cost curve on a sustainable basis, and in particular, whether you think Europe’s position can improve a...
Show response
Fitterling said Europe benefiting from byproduct credit tightness and closer naphtha access. Does not change long-term European outlook but gives breathing room for smooth shutdowns. Carter confirmed increased European operating rates and expects Q2 margin improvement.
Calendar 2025 Q4
Is this it? One more year delay and then 100% moving forward?
Show response
Fitterling confirmed two-year delay is it; cost increase mostly from capitalized interest. No serious partner inquiry but open to value-creating arrangements including creative finance.
Calendar 2025 Q3
Wondering if we could just get a bit of a reconciliation about the third quarter
Show response
Carter cited higher integrated margins from growth assets and cost savings showing up visibly at ~$75M vs expected $50M. Tate added $1.6B sequential cash flow improvement from working capital, LT agreements and earnings.
Calendar 2025 Q2
I'm wondering if you can contextualize the dividend and your operating net income on a go-forward basis
Show response
Tate said mid-cycle earnings unchanged but timeline extended. Not trying to solve solely with dividend; cost reductions and earnings growth also in flight.
Calendar 2025 Q1
I'm curious if the board came to that conclusion sort of before or after April 2
Show response
Fitterling explained minimal impact at current stage, won't revisit until end of year. Looking for supply-demand tightening and tariff clarity.
Calendar 2024 Q4
if I could just ask you to revisit the three bridge items we talked about on the last call
Show response
Fitterling gave detailed walkthrough of all three items: operating rates improving but not expansionary, turnarounds flat YoY, growth projects starting mid-year.
Show 6 more companies
ECLEcolab7 questions · 7 reporting periods · 0 of 7 challenging
Calendar 2026 Q2
wondering if you can tell us where you are in that journey given it sounds like the growth rate of CoolIT
Show response
Beck confirmed no change to the asset-light plan while flagging faster growth; Kirkland said company CapEx stays around 7% for the next couple of years given growth-engine investment.
Calendar 2026 Q1
maybe you could just unpack the margin performance in Global Water, the decline
Show response
Beck noted overall water OI was roughly flat, but ex-Paper/Heavy, water grew mid-single on revenue and high single on OI. Kirkland noted Ovivo geography between GM and SG&A.
Calendar 2025 Q4
I'm just wondering if your assessment is that, you know, this will probably be the last raise to it or if you still think there's opportunity there
Show response
Beck attributed savings acceleration to AI agent technology deployment with no external benchmark. Ranked #9 on Fortune AI list. Kirkland noted incremental $200M from savings already realized will split roughly evenly over 2026-2027. Long-term SG&A leverage target nearly doubled to 25-50bps from historical 20-30bps.
Calendar 2025 Q3
where will you be in terms of sort of the work you wanted to do with that top 35?
Show response
Beck outlined phased rollout: started with 3 customers, moved to internal Mag 7 in 2025, expanding to top 20 and emerging 15 in 2026. Food & Beverage United (Hygiene + Water in North America) is best example of results, with growth trends shifting higher.
Calendar 2025 Q2
I believe, in your prepared remarks, and please correct me if I'm wrong, you mentioned that you're maxed out on capacity in certain parts of the Water business
Show response
Beck clarified capacity constraint is in Life Sciences water purification, not broader Water. Planned European plant maintenance limited Q2 production. Pest intelligence shift expected in under 5 years with digital capabilities competitors lack.
Calendar 2025 Q1
in the first quarter, were there still sort of adverse costs associated with that?
Show response
Beck confirmed some Q1 cost spillover but safety performance improved dramatically. Dashcams installed in most vehicles reducing incidents. Moving behind them.
Calendar 2024 Q4
it's in both data centers and in pest where you've had to make some meaningful investment to go after that business
Show response
Beck described early-stage investment in direct chip cooling and water circularity for fabs. Working with largest tech companies. Pay-as-you-go approach.
SHWThe Sherwin-Williams Company7 questions · 7 reporting periods · 0 of 7 challenging
Calendar 2026 Q2
Can I ask for a little more color on the consumer brands margins? Obviously, strong. Improvement.
Show response
Meisenzahl split the 210bp gain evenly between core operating leverage and favorable non-operating items, conceding margins would be flattish sequentially without them.
Calendar 2026 Q1
Could you talk a little bit about the margin improvement in Consumer Brands
Show response
Ben attributed improvement to supply chain simplification, continuous improvement culture, and favorable premium gallon mix. Confirmed no cost reallocation between segments. Expects low-20s margin to continue.
Calendar 2025 Q4
Wondering if you can help us bridge Consumer Brands from the fourth quarter performance on the top line up about 25%
Show response
Ben detailed Suvenil annualization through Q3 2026, underlying DIY still challenged, FX headwind from LatAm in second half.
Calendar 2025 Q3
I wanted to ask on the investment spending. We're a bit more than 2 years into it.
Show response
Al detailed disciplined tracking by store and rep territory; stores in densest markets reach profitability faster; res repaint reps delivered measurable returns.
Calendar 2025 Q2
in PSG, which of the six subsegments do you think these incremental competitive dynamics will lead to the most share in?
Show response
Heidi pointed to commercial, new residential, and property maintenance as the biggest competitive-dynamics opportunities; res repaint share gains already showing. Al highlighted SHW's 6-year CAGR vs industry volume declines since 2020.
Calendar 2025 Q1
Could you talk a little bit more about COGS and gross margins, just because you had volume down across the three segments?
Show response
Al cited price effectiveness in Paint Stores plus supply chain efficiencies and simplification work as the three gross margin drivers; said SG&A wasn't flexed, proactive H2 2024 planning against soft demand.
Calendar 2024 Q4
the 80 million associated with the new headquarters
Show response
Al characterized 2025 as a transition year, roughly $20M of $80M being moving/decommissioning, and said environmental is returning to normal levels after 2024 credits rather than a true step-up.
LYBLyondellBasell6 questions · 6 reporting periods · 0 of 6 challenging
Calendar 2026 Q2
Wondering if you could talk a little bit about the feedstock mix.
Show response
Foley said flexible naphtha crackers plus a rising-crude environment lifted co-product credits (propylene, butadiene, fuel components).
Calendar 2026 Q1
what level of profitability and you can give us a wide range, would you expect for the second quarter
Show response
Peter contextualized: sold assets contributed small or negative earnings. European portfolio now focused on more differentiated products with ~1Mt ethylene, 1.5Mt PE and slightly more PP capacity. Historic LYB mid-cycle margins increasing from 18% to 21%+ from portfolio measures. EUR 110M/yr CapEx and EUR 400M/yr fixed cost reduction from Velogy scope. Kim added Europe typically sees 25% polymer imports but Strait of Hormuz disruption means supply is very tight.
Calendar 2025 Q4
how would you assess your opportunity there in '26 versus 2025
Show response
Aaron expects normalization after volatile 2025 with typical seasonal patterns. Watching crude closely, WTI up $8/barrel over the month from geopolitical unrest. Started 2026 with low inventories. US Gulf Coast freeze outages created some upward price movement. Peter noted 2025 average oxyfuels margins were actually slightly above historical averages despite volatility.
Calendar 2025 Q2
does that include the potential benefit of the $110 million -- EUR 110 million reduction that you would get if the European asset sale closes? And then my actual question is if you could talk a lit...
Show response
Agustin clarified $1.4B 2026 CapEx is on existing base; European asset sale would provide further $110M reduction. Aaron explained VAM transition to silica-based catalyst across 3 reactors starting late 2025 through 2028. $35M precious metal sales in Q2. Material margin impact not expected until after full reactor conversion.
Calendar 2025 Q1
I'd be curious to hear your thoughts on the European stimulus. It seems like you're enthusiastic
Show response
Peter acknowledged European stimulus is early stage with much work needed before legislation. More optimistic about PPWR circular regulation creating a defined market for MoReTec products by 2026. Mass balance implementation act progressing.
Calendar 2024 Q4
suggesting that we might finally see some meaningful rationalization there
Show response
Peter confirmed European capacity shutdowns are real and accelerating. Said LYB's own European strategic review is progressing well but nothing to announce yet. Technology licensing is slowing as global polyolefin capacity additions subside.
MOSMosaic Company (The)6 questions · 6 reporting periods · 0 of 6 challenging
Calendar 2026 Q2
you were previously expecting about a $400 million outflow of working capital through the course of the year
Show response
Bodine reaffirmed the $300-500 million release, bulk in Q4. Luciano said Brazil prepayments dropped sharply on changed buyer behavior, shifting collections to Q4; he expects roughly one-third of the release in Q3, two-thirds in Q4.
Calendar 2025 Q4
I think the Street had CapEx coming down about $300 million from '25 to '26
Show response
Bodine described $1.5B as ceiling/worst-case with potential upside. Simultaneous gypsum stacks at New Wales, Bartow, Louisiana plus Tapira tailings dam and Two Four Corners clay settling areas. These are lumpy investments that don't recur for 4-16 years. Luciano noted $346M raw material inventory increase was roughly half rock/WIP and half sulfur-ammonia. Rock inventory provides buffer during mine area transitions at South Fort Meade.
Calendar 2025 Q3
How much of that is at the mine or one of your facilities versus perhaps on consignment with the customer
Show response
Luciano stated inventory is distributed across Midwest warehouses, river barges, and Florida finished goods yards. Well-positioned geographically to move quickly once demand returns. Did not provide a specific breakdown between company-held and consignment positions.
Calendar 2025 Q2
That asset health target that you have of 85% to 95% is based on turnaround timing
Show response
Bodine explained the 85-95% asset health range reflects normal turnaround cycling (e.g., sulfuric acid on 3-year cycles) rather than run-of-the-mill unplanned outages. The metric intentionally allows for routine minor downtime but excludes extraordinary unplanned events. Post-reliability investment, management does not expect extraordinary unplanned downtime to recur.
Calendar 2025 Q1
Are there any other line items in cash flow from operations that are going to be material deviations, either headwinds or tailwinds this year versus last year
Show response
Luciano stated no abnormal cash flow components expected for 2025. Incremental EBITDA flows to cash after tax minus $150M working capital increase for Brazil. Declined to provide a specific cash flow conversion percentage but gave directional framework for modeling.
Calendar 2024 Q4
Can you talk about how you view the CapEx level now? Obviously, it's down versus the last few years, but do you think this is the right level
Show response
Ciani stated maintenance CapEx reduction of $200-300M is targeted over coming years while preserving $100-150M annual growth investment. Working capital will build in H2 due to volume growth, with stronger cash flows expected in 2026.
PPGPPG Industries6 questions · 6 reporting periods · 2 of 6 challenging
Calendar 2026 Q2
I just wanted to ask on buybacks. The pace decelerated in 2Q versus 1Q, but your cash flow was better.
Show response
Fully answered: explained the $65 million bolt-on offset, the quarterly deployment process, and said nothing big is in the M&A pipeline.
Calendar 2026 Q1
can you just help us understand why the margin contraction was so great and how to think about it through the balance of the year?
Show response
Knavish identified two drivers: (1) China auto builds down well into double digits in Q1, high scale/leverage market so declines magnify margin impact; (2) still rolling off deflationary-cycle index contracts in automotive and packaging businesses through Q2. Expects sequential margin improvement from incremental volume growth, price realization, and cost management. Morales added that on 2-year stack basis China is almost flat, a comp issue.
Calendar 2025 Q4
I think third quarter claims were down mid-single digits, but 4Q claims are back down high singles. So you noted, Tim, that December was only down 2%
Show response
Knavish gave comprehensive refinish update: insurance premium CAGR moderating from 16% to 3%; December claims -2% (green shoot); distributor fill-in orders starting in December; winning large new potential customers; new digital tool 'mix and shake' launched; first AI-formulated refinish product launched. H1 destocking, H2 normalization reaffirmed.
Calendar 2025 Q3
wondering if you could speak a little bit about the M&A environment, both large and small
Show response
Knavish reiterated organic growth as tip of spear, M&A secondary but not excluded. Looked at Brazil architectural and recent auto refinish/pretreatment opportunity. Some bolt-ons being evaluated. Must be right asset, right price, right time.
Calendar 2025 Q2
what you're hearing from customers that's giving you confidence that there'll be a pickup in the large project volume in 3Q and presumably more so in 4Q
Show response
Knavish cited projects in-flight resuming, high confidence from ground contacts that presidential agreement will open floodgates. Mexico's structural advantage of proximity cannot be tariffed away. Morales quantified: Mexico up modestly to mid-single-digits in H2 guidance, modest total PPG impact.
Calendar 2025 Q1
do you still expect segment margins to be up 50 basis points for the full year? And then if I could also ask, my recollection is that usually the EPS guidance does not include the benefit from shar...
Show response
Morales confirmed both points: 50bps full-year margin target unchanged, and EPS guide does not include share repurchase benefit, consistent with prior practice.
LINLinde plc5 questions · 5 reporting periods · 1 of 5 challenging
Calendar 2026 Q2
Did you all change anything in your guidance assumptions relative to what you had assumed back at the start of the year?
Show response
Matthew confirmed guidance was left intact with no material change to helium assumptions; contribution positive but margin gross-up dilutive.
Calendar 2026 Q1
Do you have the capacity you need to get there? Or should we be anticipating some type of capacity increase
Show response
White explained phased approach: early-stage longer logistics, then dedicated infrastructure as launch cadence stabilizes. Working with major and emerging providers. Combination of sale of gas and sale of plant, similar to large on-site model.
Calendar 2025 Q4
You mentioned $400 million of bolt-ons were completed in 2025
Show response
Matt said acquisitions contributing ~1% to top line from $400-500M annual spend. Concentrated in North America with some Asia (China, South Pacific). Synergies at full run rate in 12-24 months. Won't lose discipline or swim out of lane.
Calendar 2025 Q3
are you getting any sense particularly maybe in Europe, that we'll see earlier than normal seasonal shutdowns
Show response
Sanjiv expects Q4 flat sequentially. Germany slow with $500B infrastructure spend not impacting until mid-2026 or Q3. UK stagnant. Nordics a bright spot but too small to move overall European context.
Calendar 2025 Q2
I wanted to ask on margins, particularly in the Americas, where margins were flat year-over-year, but you did have positive price and volume
Show response
Matt attributed to quarterly noise and some home care mix impact. Sanjiv reiterated 30-50 basis points margin expansion expectation across all segments.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| ALB Albemarle Corporation | 13 | 0%none of 13 questions |
| DD DuPont | 8 | 0%none of 8 questions |
| APD Air Products | 7 | 14%1 of 7 questions |
| CF CF Industries | 7 | 14%1 of 7 questions |
| CTVA Corteva | 7 | 0%none of 7 questions |
| DOW Dow Inc. | 7 | 0%none of 7 questions |
| ECL Ecolab | 7 | 0%none of 7 questions |
| SHW The Sherwin-Williams Company | 7 | 0%none of 7 questions |
| LYB LyondellBasell | 6 | 0%none of 6 questions |
| MOS Mosaic Company (The) | 6 | 0%none of 6 questions |
- ALBAlbemarle Corporation · 13 questions0%none of 13 questions
- DDDuPont · 8 questions0%none of 8 questions
- APDAir Products · 7 questions14%1 of 7 questions
- CFCF Industries · 7 questions14%1 of 7 questions
- CTVACorteva · 7 questions0%none of 7 questions
- DOWDow Inc. · 7 questions0%none of 7 questions
- ECLEcolab · 7 questions0%none of 7 questions
- SHWThe Sherwin-Williams Company · 7 questions0%none of 7 questions
- LYBLyondellBasell · 6 questions0%none of 6 questions
- MOSMosaic Company (The) · 6 questions0%none of 6 questions
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q4 | 12 | 0%none of 12 questions | 9 |
| 2025 Q1 | 12 | 0%none of 12 questions | 10 |
| 2025 Q2 | 12 | 8%1 of 12 questions | 11 |
| 2025 Q3 | 11 | 9%1 of 11 questions | 9 |
| 2025 Q4 | 14 | 7%1 of 14 questions | 11 |
| 2026 Q1 | 13 | 15%2 of 13 questions | 11 |
| 2026 Q2 | 12 | 0%none of 12 questions | 12 |
- 2024 Q412 questions · challenge rate 0% (none of 12 questions) · 9 companies
- 2025 Q112 questions · challenge rate 0% (none of 12 questions) · 10 companies
- 2025 Q212 questions · challenge rate 8% (1 of 12 questions) · 11 companies
- 2025 Q311 questions · challenge rate 9% (1 of 11 questions) · 9 companies
- 2025 Q414 questions · challenge rate 7% (1 of 14 questions) · 11 companies
- 2026 Q113 questions · challenge rate 15% (2 of 13 questions) · 11 companies
- 2026 Q212 questions · challenge rate 0% (none of 12 questions) · 12 companies
Topics
Topics tagged on this analyst’s questions.
- Capital Allocation27
- Margin25
- Capex Investment21
- Cost Pressure11
- Demand11
- Competitive Dynamics10
- M&A8
- Pricing6
- Supply Chain6
- Macroeconomic5
Show all 18 topics
- Guidance Reliability4
- Regulation Policy4
- Inventory3
- Revenue Growth3
- Innovation & R&D2
- Geographic Expansion2
- Cloud & AI2
- Fx1